Pay in 4 interest-free payments of $5.90 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
The synergistic effect of activating all three receptors simultaneously promotes significant weight loss and better metabolic control than other existing GLP-1 receptor agonists, such as semaglutide (Wegovy and Ozempic), liraglutide, dulaglutide, and dual-agonists like tirzepatide (Mounjaro and Zepbound)
Understanding your individual peptide sensitivitysuch as variants in the GLP1R genecan help explain how your body responds to each dose
Transdermal delivery systems could potentially offer advantages over subcutaneous injections, including improved patient acceptability and reduced injection-site reactions
Ro sells FDA-approved brand-name drugs: Wegovy, Zepbound, cash-pay Ozempic, and a new oral orforglipron option added in April 2026
To ensure the safety of both the mother and the baby, it is recommended to avoid using this medication during pregnancy and while breastfeeding.2
